No Severe Adverse Effects from Intravitreally Injected Putative Adipose Tissue-Derived Stem Cells

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Therapy

Background:

• Investigating the safety and efficacy of adipose tissue-derived stem cells (ASCs) for ocular conditions.
• Evaluating potential treatments for non-arteritic anterior ischemic optic neuropathy (NAION).

Observation:

• A patient received bilateral intravitreal injections of putative ASCs for NAION treatment.
• The patient was monitored for 8 and 18 months post-injection.
• Cells were observed to remain inert in the vitreous without therapeutic effect or complications.

Findings:

• Intravitreally injected ASCs showed no therapeutic benefits or adverse events in the observed period.
• Cells were successfully removed via vitrectomy.
• No evidence of optic nerve or retinal integration of the injected cells was found.

Implications:

• This case suggests that intravitreal ASC injections may be safe in the short-term, contrary to some reports.
• Further research is needed to determine the long-term safety and potential efficacy of ASCs in ophthalmology.
• Highlights the importance of rigorous clinical trials for novel stem cell therapies.